Letybo
Letybo is a neuromodulator that minimizes fine lines and wrinkles and can also be used for facial shaping.
How does Letybo work?
Letybo is a neuromodulator that originates out of South Korea. When injected, Letybo safely and temporarily blocks nerve impulses from entering a muscle to reduce it’s activity. When a muscle is no longer contracting, it reduces the wrinkling you would normally see when making an expression.
In addition to on-label uses, Letybo can be used to create facial symmetry or for facial shaping. Common areas for Letybo treatment include elevating the brow, jawline slimming, reduction of TMJ pain, reversing downturned lips or a downturned nasal tip, uneven eye size or a “jelly roll” under the eye, correcting a “gummy smile” or “bunny lines”, and reducing neck bands.
Expert knowledge of facial anatomy is the key to outstanding results. Precise dose and placement determine the success of the treatment.
Is Letybo safe?
The FDA has approved Letybo. Like any surgical or non-surgical procedure, there are risks. As an international teacher and trainer of other physicians in facial anatomy and injection techniques, Dr. Cox stresses the importance of finding an experienced physician who understands the finer points of injectable treatment. Dr. Cox performed clinical trials for Letybo right here in Chapel Hill and is internationally recognized for her skills as an injector.
Letybo downtime
Letybo treatments are well tolerated. The treatment is comprised of a series of precise injections with a very small needle. This process only takes a few minutes. There is no downtime associated with Letybo.
Letybo results
You will begin to see results from Letybo within three to four days. Full results will appear two weeks after treatment. Letybo typically lasts three to four months. One Letybo treatment will reduce or eliminate dynamic wrinkles in the treatment area. Wrinkles that are etched in (remain visible at rest) will need multiple sessions for optimal results. In the case of etched lines, additional treatment modalities may be needed.
Related Clinical Trials
New Neuromodulator 1610-54
Status: Completed
Dr. Cox is serving as principal investigator in the study “Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of LetibotulinumtoxinA in the Treatment of Glabellar Lines in Comparison With Placebo Followed by an Open Label Extension Study.” This study is evaluating a new Botox-like product for treatment of vertical lines between the eyebrows. As companies develop similar products with slightly different characteristics, there’s opportunity for skilled injectors to tailor treatments by selecting products best matched to an individual’s unique facial anatomy. It’s customized aesthetic medicine and we’re excited about the possibilities. The study began in October 2016 and concluded in January 2018.
Glabellar Neuromodulator 1904-66
Status: Completed
Dr. Cox has completed work on this study “A Randomized double blind Phase 3 study to assess the efficacy and safety of [product] in the treatment of glabellar lines in comparison with placebo followed by an open label extension study” serving as the principal investigator. This study evaluated the effectiveness of a new neuromodulator, Letybo, when used in the glabellar (between the brows) area. The study began in July of 2019 and ended in April of 2021. This product was FDA approved in 2024.